Last reviewed · How we verify
Revivon (DIPRENORPHINE)
Diprenorphone (Revivon) is a marketed drug that binds to kappa-type opioid receptors, though its primary indication and revenue figures are not specified. A key strength of Revivon is its patent protection until 2028, providing a period of market exclusivity. However, the primary risk is the presence of multiple competitors targeting the same receptor, including off-patent alfentanil and patent-protected alvimopan and amiodarone.
At a glance
| Generic name | DIPRENORPHINE |
|---|---|
| Target | Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opioid System Cerebral Activity in Endurance Sportswomen - Addiction or Denutrition ? [11C]Diprenorphine PET Study (NA)
- Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study (NA)
- A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects (NA)
- The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Revivon CI brief — competitive landscape report
- Revivon updates RSS · CI watch RSS